[{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Parexel"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Ispen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ispen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ispen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ispen \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"Denileukin Diftitox","moa":"Elongation factor 2 | Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Citius Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Citius Pharmaceuticals"},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Bharat Serums & Vaccines ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bharat Serums & Vaccines ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bharat Serums & Vaccines ltd \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ficlatuzumab","moa":"Hepatocyte growth factor","graph1":"Oncology","graph2":"Phase III","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tivozanib HCl","moa":"Platelet-derived growth factor receptor beta | Vascular endothelial growth factor receptor | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase III","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocon Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocon Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Nanopharmaceutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"3-aminopyridine-2-carboxaldehyde thiosemicarbazone","moa":"||RNR","graph1":"Oncology","graph2":"Phase III","graph3":"Nanopharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanopharmaceutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nanopharmaceutics \/ Undisclosed"},{"orgOrder":0,"company":"Cipla","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"CBT124","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cipla \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cipla \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharma Advanced Research Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"SPARC1507","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Sun Pharma Advanced Research Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharma Advanced Research Company \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharma Advanced Research Company \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Parexel | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Parexel | Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Parexel | Bristol Myers Squibb"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Astellas Pharma"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Julie E. Bauman","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Ficlatuzumab","moa":"Hepatocyte growth factor","graph1":"Oncology","graph2":"Phase III","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Julie E. Bauman","highestDevelopmentStatusID":"10","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Julie E. Bauman"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"James J. Lee","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Ficlatuzumab","moa":"Hepatocyte growth factor","graph1":"Oncology","graph2":"Phase III","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AVEO Pharmaceuticals, Inc \/ James J. Lee","highestDevelopmentStatusID":"10","companyTruncated":"AVEO Pharmaceuticals, Inc \/ James J. Lee"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
